0001192482-19-000388.txt : 20191107 0001192482-19-000388.hdr.sgml : 20191107 20191107210509 ACCESSION NUMBER: 0001192482-19-000388 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191107 FILED AS OF DATE: 20191107 DATE AS OF CHANGE: 20191107 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Quaker BioVentures II LP CENTRAL INDEX KEY: 0001497725 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39130 FILM NUMBER: 191201890 BUSINESS ADDRESS: STREET 1: QUAKER BIOVENTURES STREET 2: 2929 ARCH STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: (215) 988-6800 MAIL ADDRESS: STREET 1: QUAKER BIOVENTURES STREET 2: 2929 ARCH STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Quaker BioVentures Capital II, L.P. CENTRAL INDEX KEY: 0001583083 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39130 FILM NUMBER: 191201891 BUSINESS ADDRESS: STREET 1: CIRA CENTER STREET 2: 2929 ARCH STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: 215-988-6800 MAIL ADDRESS: STREET 1: CIRA CENTER STREET 2: 2929 ARCH STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TELA Bio, Inc. CENTRAL INDEX KEY: 0001561921 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 455320061 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 GREAT VALLEY PARKWAY, SUITE 24 CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 484-320-2930 MAIL ADDRESS: STREET 1: 1 GREAT VALLEY PARKWAY, SUITE 24 CITY: MALVERN STATE: PA ZIP: 19355 3 1 edgar.xml PRIMARY DOCUMENT X0206 3 2019-11-07 0 0001561921 TELA Bio, Inc. TELA 0001497725 Quaker BioVentures II LP 150 MONUMENT ROAD, SUITE 207 BALA CYNWYD PA 19004 0 0 1 0 0001583083 Quaker BioVentures Capital II, L.P. 150 MONUMENT ROAD, SUITE 207 BALA CYNWYD PA 19004 0 0 1 0 Common Stock 29288 D Series A Preferred Stock Common Stock 345489 D Series B Preferred Stock Common Stock 516947 D Warrant 1.16 2017-01-18 2027-01-18 Series B Preferred Stock 446813 D These securities are owned of record by Quaker BioVentures II, L.P. ("Quaker"). Quaker BioVentures Capital II, L.P. ("Quaker Capital") is the general partner of Quaker, has voting and dispositive power over the securities held by Quaker, and thus may be deeemd to beneficially own these securities. Voting and investment determinations made by Quaker Capital with respect to the securities held by Quaker are made by an investment committee of Quaker Partners. Quaker Capital disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein. Shares of Series A and Series B Preferred Stock (collectively, the "Preferred Stock") have no expiration date and are convertible, at the option of the holder, into shares of Common Stock at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Third Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). The shares of Preferred Stock will automatically convert into shares of Common Stock at the then-effective conversion rate for no additional consideration (subject to the payment in cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the closing of the Issuer's initial public offering. Shares of Series A Preferred Stock are convertible into shares of Common Stock at a 1-for-1 conversion rate. Shares of Series B Preferred Stock are convertible into shares of Common Stock at a 1-for-1 conversion rate. Quaker BioVentures II, L.P. By: Quaker Bioventures Capital II, L.P., its general partner By Quaker BioVentures Capital II, LLC, its general partner By: /s/ Adele C. Oliva, Executive Manager 2019-11-07 Quaker Bioventures Capital II, L.P., its general partner By: Quaker BioVentures Capital II, LLC, its general partner By: /s/ Adele C. Oliva, Executive Manager 2019-11-07